產(chǎn)品[
TT 人甲狀腺導(dǎo)管癌細(xì)胞
]資料
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
TT 人甲狀腺導(dǎo)管癌細(xì)胞
產(chǎn)品型號:
CRL-1803
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
CRL-1803 TT 人甲狀腺導(dǎo)管癌細(xì)胞， ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
TT 人甲狀腺導(dǎo)管癌細(xì)胞
的詳細(xì)介紹
CRL-1803 TT 人甲狀腺導(dǎo)管癌細(xì)胞
|
|
CRL-1803?
|
|
|
|
|
TT
|
|
|
SS Leong
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: thyroid
Tissue: medulla
Disease: carcinoma
|
|
|
calcitonin; carcinoembryonic antigen (CEA) [21867]
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
Amelogenin: X
CSF1PO: 10,13
D13S317: 11
D16S539: 12,13
D5S818: 12,13
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 16,18
|
|
|
aneuploid with several markers; modal number = 40; range = 32 to 86 [21867]
|
|
|
77 years
|
|
|
female
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Twice per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
83 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2004
recommended serum:ATCC 30-2020
|
|
|
21867: . Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.
32264: Behr TM, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 57: 5309-5319, 1997. PubMed: 9393755
|
|
